DENV2 (strain Thailand/16681/1984) NS1 protein, His Tag (MALS verified)

1/5
+2 View all
Product Number/Spec
Price
Availability
Menge
NS1-D52H3-100ug
$410.00
In Stock - Delivery in 1-2 business days
NS1-D52H3-1mg (500ug X 2)
$2,680.00
In Stock - Delivery in 2 weeks
NS1-D52H3
Product Amount :
$ 0
0
Add to Cart
New Product Suggestion Request Quote
Contact Us
Contact Us
Product Amount:
$ 0
0
Add to Cart
  • Product Details
  • Data Display
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

Non-structural protein 1/NS1 (DENV)

Source

DENV2 (strain Thailand/16681/1984) NS1 protein, His Tag (NS1-D52H3) is expressed from human 293 cells (HEK293). It contains AA Asp 776 - Ala 1127 (Accession # P29990-1).

Predicted N-terminus: Asp 776

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 41.8 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

The protein is designed as a tetramer.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background Introduction

Dengue is a mosquito-borne viral disease widely spread all over the world transmitted by 4 serotypes of dengue virus (DENV). The symptoms range from mild dengue fever to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with high mortality. Currently, most of the studies on DENV vaccines emphasize on its envelope protein (i.e., Sanofi’s tetravalent dengue vaccine Dengvaxia). However, the fact pointing out that the vaccines with Envelope protein may could have negative effect on people never infected by DENV which makes the non-structural protein NS1 become another great target for vaccine research with its ability to avoid Antibody Dependent Enhancement.